The first allosteric TYK2 inhibitor, deucravacitinib, has been approved by the FDA for the treatment of plaque psoriasis and is being used in clinical trials for other autoimmune diseases including inflammatory bowel disease (IBD). This evidence concerns the gene TYK2 and autoimmune disease.